Clopidogrel treatment group

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Mar 22, 2023 โ†’ Dec 31, 2031

About Clopidogrel treatment group

Clopidogrel treatment group is a approved stage product being developed by Yuhan for Coronary Artery Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05845489. Target conditions include Coronary Artery Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05845489ApprovedRecruiting

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
ExenatideEli LillyPhase 3
77
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
77
statins, ezetimibe + Combination therapyYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
85
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
PrasugrelDaiichi SankyoApproved
85
ADP receptor inhibitorsDaiichi SankyoPre-clinical
23
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
52
prasugrel + clopidogrelDaiichi SankyoPhase 1
33
Prasugrel + ClopidogrelDaiichi SankyoApproved
85
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
85